Patents by Inventor Janelle Comita-Prevoir

Janelle Comita-Prevoir has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds and methods for treating bacterial infections
    Patent number: 11046694
    Abstract: Provided herein are antibacterial compounds represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein X, Y, R4, R5, and R6 are as defined herein. Also provided are pharmaceutical compositions comprising the compounds of Formula I.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: June 29, 2021
    Assignee: Entasis Therapeutics, Inc.
    Inventors: Janelle Comita-Prevoir, Thomas Francois Durand-Reville, Satenig Guler, Jan Romero, Mark Sylvester, Ruben Tommasi, Camilo Velez-Vega, Xiaoyun Wu, Jing Zhang
  • Beta-lactamase inhibitor compounds
    Patent number: 10800778
    Abstract: The present invention is directed to compounds which are beta-lactamase inhibitors. The compounds and their pharmaceutically acceptable salts are useful in combination with beta-lactam antibiotics, for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant organisms. The present invention includes compounds according to Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of R1, R2, R3, R4, R5 and R6 are described herein.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: October 13, 2020
    Assignee: Entasis Therapeutics Limited
    Inventors: Janelle Comita-Prevoir, Thomas Francois Durand-Reville, Lise Gauthier, John O'Donnell, Jan Romero, Ruben Tommasi, Jeroen Cunera Verheijen, Frank Wu, Xiaoyun Wu, Jing Zhang
  • COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS
    Publication number: 20200165251
    Abstract: Provided herein are antibacterial compounds represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein X, Y, R4, R5, and R6 are as defined herein. Also provided are pharmaceutical compositions comprising the compounds of Formula I.
    Type: Application
    Filed: May 8, 2018
    Publication date: May 28, 2020
    Inventors: Janelle Comita-Prevoir, Thomas Francois Durand-Reville, Satenig Guler, Jan Romero, Mark Sylvester, Ruben Tommasi, Camilo Velez-Vega, Xiaoyun Wu, Jing Zhang
  • BETA-LACTAMASE INHIBITOR COMPOUNDS
    Publication number: 20190202832
    Abstract: The present invention is directed to compounds which are beta-lactamase inhibitors. The compounds and their pharmaceutically acceptable salts are useful in combination with beta-lactam antibiotics, for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant organisms. The present invention includes compounds according to Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of R1, R2, R3, R4, R5 and R6 are described herein.
    Type: Application
    Filed: September 15, 2017
    Publication date: July 4, 2019
    Applicants: Entasis Therapeutics Limited, Entasis Therapeutics Limited
    Inventors: Gregory S. Basarab, Janelle Comita-Prevoir, Thomas Francois Durand-Reville, Lise Gauthier, Bill Moss, John O'Donnell, Jan Romero, Ruben Tommasi, Jeroen Cunera Verheijen, Frank Wu, Xiaoyun Wu, Jing Zhang
  • ?-lactamase inhibitor compounds
    Patent number: 9623014
    Abstract: The present invention is directed to compounds which are beta-lacatamase inhibitors. The compounds and their pharmaceutically acceptable salts, are useful in combination with beta-lactam antibiotics, or alone, for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant organisms. The present invention includes compounds according to formula (Ia): or a pharmaceutically acceptable salt thereof, wherein the values of R1, R2, R3 and R4 are described herein.
    Type: Grant
    Filed: February 29, 2016
    Date of Patent: April 18, 2017
    Assignee: Entasis Therapeutics Limited
    Inventors: Helen Mcguire, Shanta Bist, Neil Bifulco, Liang Zhao, Ye Wu, Hoan Huynh, Hui Xiong, Janelle Comita-Prevoir, Daemian Dussault, Bolin Geng, Brendan Chen, Thomas Francois Durand-Reville, Satenig Guler
  • BETA-LACTAMASE INHIBITOR COMPOUNDS
    Publication number: 20160175290
    Abstract: The present invention is directed to compounds which are beta-lacatamase inhibitors. The compounds and their pharmaceutically acceptable salts, are useful in combination with beta-lactam antibiotics, or alone, for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant organisms. The present invention includes compounds according to formula (Ia): or a pharmaceutically acceptable salt thereof, wherein the values of R1, R2, R3 and R4 are described herein.
    Type: Application
    Filed: February 29, 2016
    Publication date: June 23, 2016
    Inventors: Helen Mcguire, Shanta Bist, Neil Bifulco, Liang Zhao, Ye Wu, Hoan Huynh, Hui Xiong, Janelle Comita-Prevoir, Daemian Dussault, Bolin Geng, Brendan Chen, Thomas Francois Durand-Reville, Satenig Guler
  • Beta-lactamase inhibitor compounds
    Patent number: 9309245
    Abstract: The present invention is directed to compounds which are beta-lacatamase inhibitors. The compounds and their pharmaceutically acceptable salts, are useful in combination with beta-lactam antibiotics, or alone, for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant organisms. The present invention includes compounds according to formula (Ia): or a pharmaceutically acceptable salt thereof, wherein the values of R1, R2, R3 and R4 are described herein.
    Type: Grant
    Filed: April 2, 2013
    Date of Patent: April 12, 2016
    Assignee: Entasis Therapeutics Limited
    Inventors: Helen McGuire, Shanta Bist, Neil Bifulco, Liang Zhao, Ye Wu, Hoan Huynh, Hui Xiong, Janelle Comita-Prevoir, Daemian Dussault, Bolin Geng, Brendan Chen, Thomas Durand-Reville, Satenig Guler
  • Beta-Lactamase Inhibitor Compounds
    Publication number: 20150073011
    Abstract: The present invention is directed to compounds which are beta-lacatamase inhibitors. The compounds and their pharmaceutically acceptable salts, are useful in combination with beta-lactam antibiotics, or alone, for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant organisms. The present invention includes compounds according to formula (Ia): or a pharmaceutically acceptable salt thereof, wherein the values of R1, R2, R3 and R4 are described herein.
    Type: Application
    Filed: April 2, 2013
    Publication date: March 12, 2015
    Applicant: ASTRAZENECA AB
    Inventors: Helen McGuire, Shanta Bist, Neil Bifulco, Liang Zhao, Ye Wu, Hoan Huynh, Hui Xiong, Janelle Comita-Prevoir, Daemian Dussault, Bolin Geng, Brendan Chen, Thomas Durand-Reville, Satenig Guler
  • 2-QUINOLINONE AND 2-QUINOXALINONE-DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS
    Publication number: 20120270864
    Abstract: The present invention relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, to their use in the treatment of bacterial infections, and to their methods of preparation.
    Type: Application
    Filed: May 18, 2012
    Publication date: October 25, 2012
    Inventors: Andrew Aydon Godfrey, Janelle Comita-Prevoir, Mark Cronin, Bolin Geng, Folkert Reck
  • 2-QUINOLINONE AND 2-QUINOXALINONE-DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS
    Publication number: 20100144717
    Abstract: The present invention relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, to their use in the treatment of bacterial infections, and to their methods of preparation.
    Type: Application
    Filed: December 15, 2006
    Publication date: June 10, 2010
    Inventors: Janelle Comita-Prevoir, Mark Cronin, Bolin Geng, Andrew Aydon Godfrey, Folkert Reck